Louise Emmett, Nuclear Medicine and PET Specialist at St VIncent’s Public Hospital Sydney, shared a post on LinkedIn:
“Nature Cancer paper evaluating the frequency and significance of early PSMA upregulation with (15 days) enzalutamide in the ENZA-p mCRPC population. This has implications for AR/PSMA therapy combination rationale. Synergistic or complementary? Likely both.
Click the link below to the full article.”
Other articles featuring Louise Emmett on OncoDaily.